32 Biosciences is taking a new approach to medicine by using our field defining research to build clinically useful, validated, precision tools to diagnose and correct Dysbiosis (microbiome imbalance), a central but underappreciated driver of disease.
The gut microbiome is a vital organ critical to health, but little understood.
The diverse bacterial communities which live in our gastrointestinal tract are collectively known as the “gut microbiota,” and their collective genes are termed the “microbiome.”
The microbiome is incredibly diverse and contains millions of genes, many of which encode enzymes and other proteins that contribute to various metabolic processes
An imbalanced gut microbiome is linked to higher disease risk.
Unhealthy gut microbiome is linked to:
These diseases cause $1.5T of economic health care burden to the US annually.
Gut Microbiome Diagnostic Tool
GB-0001
Targeted Microbiome Therapeutics
CS-0003
32 Biosciences is a hand-selected group of industry leaders, and includes 35 scientists, business partners, and advisors.
